# Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

> **NCT05964946** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Gouty Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05964946
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-24
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964946, "Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05964946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*